Literature DB >> 11103943

Loss of heterozygosity, allele silencing and decreased expression of p73 gene in breast cancers: prevalence of alterations in inflammatory breast cancers.

J C Ahomadegbe1, S Tourpin, M Kaghad, L Zelek, M Vayssade, M C Mathieu, F Rochard, M Spielmann, T Tursz, D Caput, G Riou, J Bénard.   

Abstract

The p73 gene is a p53 homologue located at 1p36-33, a region submitted to deletions in breast cancer (BC) and putatively imprinted. To study whether p73 was associated with breast carcinogenesis, loss of heterozygosity (LOH), allele expression and transcript levels were assessed in 59 BC, including 39 BC presenting no inflammatory symptoms (NBC) and 20 inflammatory BC (IBC). IBC is a rare but aggressive form of cancer with a very poor prognosis. Normal breast epithelium (BE) and lymphocytes from patients were used as controls. StyI polymorphism generating GC and/or AT alleles was used to select 22 heterozygous patients. p73 LOH was significantly higher in IBC than in NBC [five of eight cases (62%) versus two of 14 cases (14%); Fisher's exact test, P=0.05]. p73 was biallelically expressed in all BE. In contrast, 12 of 16 (75%) BC were monoallelically expressed, showing that allele silencing was significantly associated with breast carcinogenesis (P=0.012), AT being the preferential silent allele (10 out of 12 tumours). p73 mRNA levels in NBC and IBC were two- and threefold lower than in BE, respectively, suggesting that decreased expression could be related to tumour aggressiveness. In conclusion, LOH, allele silencing and decreased expression of the p73 gene may play a role in breast carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11103943     DOI: 10.1038/sj.onc.1203914

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  15 in total

1.  Role of ERRF, a novel ER-related nuclear factor, in the growth control of ER-positive human breast cancer cells.

Authors:  Dan Su; Xiaoying Fu; Songqing Fan; Xiao Wu; Xin-Xin Wang; Liya Fu; Xue-Yuan Dong; Jianping Jenny Ni; Li Fu; Zhengmao Zhu; Jin-Tang Dong
Journal:  Am J Pathol       Date:  2012-03       Impact factor: 4.307

2.  The type III TGF-beta receptor suppresses breast cancer progression.

Authors:  Mei Dong; Tam How; Kellye C Kirkbride; Kelly J Gordon; Jason D Lee; Nadine Hempel; Patrick Kelly; Benjamin J Moeller; Jeffrey R Marks; Gerard C Blobe
Journal:  J Clin Invest       Date:  2006-12-07       Impact factor: 14.808

3.  Association between the p73 gene G4C14-to-A4T14 single nucleotide polymorphism and risk of cervical cancer by high resolution melting and PCR with confronting two-pair primers in a Chinese population.

Authors:  Haiyan Guo; Shaodi Yang; Lijian Xu; Ding Li; Jianxin Tang; Shuangshaung Wang; Benjie Wei; Zhengchun Liu
Journal:  Oncol Lett       Date:  2016-06-01       Impact factor: 2.967

4.  1alpha,25-Dihydroxyvitamin D3 potentiates cisplatin antitumor activity by p73 induction in a squamous cell carcinoma model.

Authors:  Yingyu Ma; Wei-Dong Yu; Pamela A Hershberger; Geraldine Flynn; Rui-Xian Kong; Donald L Trump; Candace S Johnson
Journal:  Mol Cancer Ther       Date:  2008-09       Impact factor: 6.261

5.  p53 Activity Dominates That of p73 upon Mdm4 Loss in Development and Tumorigenesis.

Authors:  Mehrnoosh Tashakori; Yun Zhang; Shunbin Xiong; M James You; Guillermina Lozano
Journal:  Mol Cancer Res       Date:  2015-11-02       Impact factor: 5.852

6.  High-resolution comparative genomic hybridization of inflammatory breast cancer and identification of candidate genes.

Authors:  Ismahane Bekhouche; Pascal Finetti; José Adelaïde; Anthony Ferrari; Carole Tarpin; Emmanuelle Charafe-Jauffret; Colette Charpin; Gilles Houvenaeghel; Jocelyne Jacquemier; Ghislain Bidaut; Daniel Birnbaum; Patrice Viens; Max Chaffanet; François Bertucci
Journal:  PLoS One       Date:  2011-02-09       Impact factor: 3.240

Review 7.  p73 as a pharmaceutical target for cancer therapy.

Authors:  Andrea Bisso; Licio Collavin; Giannino Del Sal
Journal:  Curr Pharm Des       Date:  2011       Impact factor: 3.116

8.  Allelic imbalance at 1p36 may predict prognosis of chemoradiation therapy for bladder preservation in patients with invasive bladder cancer.

Authors:  H Matsumoto; H Matsuyama; K Fukunaga; S Yoshihiro; T Wada; K Naito
Journal:  Br J Cancer       Date:  2004-09-13       Impact factor: 7.640

9.  Pirh2, an E3 ligase, regulates the AIP4-p73 regulatory pathway by modulating AIP4 expression and ubiquitination.

Authors:  Rami Abou Zeinab; H Helena Wu; Yasser Abuetabh; Sarah Leng; Consolato Sergi; David D Eisenstat; Roger P Leng
Journal:  Carcinogenesis       Date:  2021-04-30       Impact factor: 4.944

10.  Role of p73 Dinucleotide Polymorphism in Prostate Cancer and p73 Protein Isoform Balance.

Authors:  L Michael Carastro; Hui-Yi Lin; Hyun Y Park; Donghwa Kim; Selina Radlein; Kaia K Hampton; Ardeshir Hakam; Babu Zachariah; Julio Pow-Sang; Jong Y Park
Journal:  Prostate Cancer       Date:  2014-07-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.